4a73aaff-d7fa-40d2-92f8-c9539055d35c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- E2F_TARGETS+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- ESTROGEN_RESPONSE_LATE+0.200
- G2M_CHECKPOINT+0.200
- GLYCOLYSIS+0.200
- MTORC1_SIGNALING+0.200
- XENOBIOTIC_METABOLISM+0.200
- BILE_ACID_METABOLISM+0.100
- DNA_REPAIR+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- ANGIOGENESIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- HEDGEHOG_SIGNALING-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- APICAL_JUNCTION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AG12-TTM1-A-1-1-R-A743-41 | — | C | 0.890 |
| 2 | TCGA-E2-A14W-01A-11R-A12D-07 | — | B | 0.874 |
| 3 | AUR-AERX-TTM1-A-1-1-R-A742-41 | — | C | 0.871 |
| 4 | fd49c74b-2a85-46cd-aaa0-dbd2f1284947 | — | — | 0.870 |
| 5 | bbeadeec-bb57-4762-8828-3bd1696748fb | — | — | 0.869 |
| 6 | BSR_20_0054redo_S62 | — | B | 0.869 |
| 7 | TCGA-QK-A8ZA-01A-11R-A39I-07 | — | — | 0.869 |
| 8 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.868 |
| 9 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.866 |
| 10 | 20120289.LumB | — | B | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |